Titan Pharmaceuticals (NASDAQ:TTNP) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNPFree Report) in a research note released on Sunday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Performance

Shares of Titan Pharmaceuticals stock opened at $3.20 on Friday. Titan Pharmaceuticals has a twelve month low of $3.03 and a twelve month high of $14.80. The business’s fifty day moving average price is $3.65 and its 200 day moving average price is $4.80.

Titan Pharmaceuticals (NASDAQ:TTNPGet Free Report) last announced its earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share for the quarter.

Titan Pharmaceuticals Company Profile

(Get Free Report)

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.

Further Reading

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.